CAR-T in Refractory Ulcerative Colitis – A Signal from the NEJM
A New Frontier: CAR-T Cells Enter the IBD Space The March 2025 New England Journal of Medicine correspondence describing a patient with treatment-refractory ulcerative colitis achieving deep, drug-free remission after CD19-directed CAR-T cell therapy has reverberated across the gastroenterology community. For the first time, a technology born in oncology appears to have induced not merely […]
FDA Grants Accelerated Approval to Wegovy for MASH: First Major Step Toward Drug-Based Liver Disease Treatment
A Milestone in MASH Therapeutics The U.S. Food and Drug Administration’s August 2025 decision to grant accelerated approval to Wegovy® (semaglutide 2.4 mg weekly) for metabolic dysfunction associated steatohepatitis (MASH) represents a watershed moment in hepatology. Until this ruling, there had been no officially sanctioned pharmacologic treatment for MASH in the United States, despite the […]
FDA Expands Indication for Omvoh (Mirikizumab) to Crohn’s Disease
Omvoh’s Expanded Approval: What It Means for IBD Therapeutics The U.S. Food and Drug Administration’s January 2025 decision to expand Omvoh® (mirikizumab-mrkz) for adults with moderately to severely active Crohn’s disease establishes a new checkpoint in inflammatory bowel disease (IBD) therapy. Already authorized for ulcerative colitis, the Lilly-developed IL-23p19 antagonist is now the first drug […]